Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2014
Price : $35 *
At a glance
- Drugs REGN 1908-1909 (Primary)
- Indications Hypersensitivity
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 09 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Nov 2013 New trial record